VERA vs. ASND, LEGN, CERE, VKTX, ITCI, JAZZ, BPMC, BBIO, IONS, and OGN Should you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), Viking Therapeutics (VKTX), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), Blueprint Medicines (BPMC), BridgeBio Pharma (BBIO), Ionis Pharmaceuticals (IONS), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical preparations" industry.
Ascendis Pharma A/S (NASDAQ:ASND ) and Vera Therapeutics (NASDAQ:VERA ) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, community ranking, dividends and media sentiment.
Vera Therapeutics has a net margin of 0.00% compared to Vera Therapeutics' net margin of -152.68%. Ascendis Pharma A/S's return on equity of -52.43% beat Vera Therapeutics' return on equity.
Ascendis Pharma A/S has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.11, indicating that its stock price is 11% more volatile than the S&P 500.
In the previous week, Ascendis Pharma A/S and Ascendis Pharma A/S both had 8 articles in the media. Vera Therapeutics' average media sentiment score of 1.27 beat Ascendis Pharma A/S's score of 0.70 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.
Vera Therapeutics has lower revenue, but higher earnings than Ascendis Pharma A/S. Vera Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.
Ascendis Pharma A/S received 386 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 65.45% of users gave Ascendis Pharma A/S an outperform vote while only 55.56% of users gave Vera Therapeutics an outperform vote.
99.2% of Vera Therapeutics shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by insiders. Comparatively, 21.7% of Vera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Ascendis Pharma A/S presently has a consensus price target of $179.44, suggesting a potential upside of 32.82%. Vera Therapeutics has a consensus price target of $42.86, suggesting a potential upside of 12.81%. Given Vera Therapeutics' higher possible upside, equities analysts plainly believe Ascendis Pharma A/S is more favorable than Vera Therapeutics.
Summary Vera Therapeutics beats Ascendis Pharma A/S on 9 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Vera Therapeutics Competitors List
Related Companies and Tools
